EUVIMEDEUVIMED entdecken
Crossref

Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data

Carlos De Las Cuevas, Emilio J Sanz iD, Sara Jiménez-Fernández iD, Georgios Schoretsanitis iD, Can-Jun Ruan iD, Jose de Leon

European Child & Adolescent Psychiatry · 2025-07 · 34 (7) · 2083-2091

DOI: 10.1007/s00787-024-02623-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Child & Adolescent Psychiatry, online erschienen am 02.12.2024. Verfasst von Carlos De Las Cuevas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dermatology and Psychiatry, Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, La Laguna, Can…. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacovigilance findings have marked clozapine use. Prescribers and package inserts worldwide focus on clozapine-induced neutropenia. The literature on clozapine adverse drug reactions (ADRs) for those under age 18 and their associated fatal outcomes is limited. Reports to the World Health Organization's global pharmacovigilance database (VigiBase) were analyzed among patients under 18 years of age extending from clozapine's introduction to June 1, 2022. There were 2825 reports of clozapine, including 42 fatal outcomes (relative lethality = 1.5% vs. 11.7% in all ages). After 280 cases were excluded (clozapine exposure during pregnancy, accidental exposure or unclear age), 2455 were included with ADRs during therapeutic use. Decreased white blood cell (WBC) count provided the most frequent aggregated ADR, accounting for 934 cases (37% of 2545), with only 1 fatal outcome (0.01%, 1/934). Suicide explained 7 of 27 (26%) non-duplicated fatal outcomes. Next in importance was clozapine-induced gastrointestinal hypomotility (CIGH) with 3 cases (11% of 27) and neuroleptic malignant syndrome with 2 cases (7% of 27). Agranulocytosis, aspiration, myocarditis, myocardiopathy and ventricular arrythmia led to single fatal cases. Based on these new findings and recent literature in all ages, to prevent fatal outcomes, child and adolescent psychiatrists need to shift their focus from severe neutropenia to other ADRs including pneumonia, respiratory aspiration and CIGH. In spite of its potential toxicity during overdoses, clozapine may have specific and strong anti-suicidal effects when compared with other antipsychotics. Child and adolescent psychiatrists need to take extreme precautions to avoid intentional overdoses when prescribing clozapine to patients with suicide risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineAntipsychotic AgentsPharmacovigilanceDrug-Related Side Effects and Adverse ReactionsHumansAdolescentChildFemaleMaleChild, PreschoolAdverse Drug Reaction Reporting SystemsNeuroleptic Malignant SyndromeDatabases, Factual

Stichwörter der Autor:innen

ChildrenClozapine/adverse effectsClozapine/therapeutic useDrug labelingPharmacovigilanceSchizophrenia

Substanzen

ClozapineAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Dermatology and Psychiatry, Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, La Laguna, Canary Islands, Spain. ccuevas@ull.edu.es.
  • Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, University of La Laguna, Campus de Ofra s/. 38071, San Cristobal de La Laguna, Canary Islands, Spain. ccuevas@ull.edu.es.
  • Department of Physical Medicine and Pharmacology, School of Medicine, Universidad de La Laguna, La Laguna, Canary Islands, Spain.
  • Hospital Universitario de Canarias, Tenerife, Spain.
  • Child and Adolescent Mental Health Unit, University Hospital Virgen de las Nieves, Granada, Spain.
  • CTS-549 Research Group (Psychiatry and Neurosciences), Granada, Junta de Andalucía, Spain.

ORCID-Profile: Emilio J Sanz, Sara Jiménez-Fernández, Georgios Schoretsanitis, Can-Jun Ruan

Zitieren

APA

De Las Cuevas, C., Sanz, E. J., Jiménez-Fernández, S., Schoretsanitis, G., Ruan, C. J., & de Leon, J. (2025). Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data. European Child & Adolescent Psychiatry, 34(7), 2083-2091. https://doi.org/10.1007/s00787-024-02623-3

Vancouver

De Las Cuevas C, Sanz EJ, Jiménez-Fernández S, Schoretsanitis G, Ruan CJ, de Leon J. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data. European Child & Adolescent Psychiatry. 2025;34(7):2083-2091. doi:10.1007/s00787-024-02623-3

BibTeX
@article{DeLasCuevas2025,
  author = {De Las Cuevas, Carlos and Sanz, Emilio J and Jiménez-Fernández, Sara and Schoretsanitis, Georgios and Ruan, Can-Jun and de Leon, Jose},
  title = {Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data},
  journal = {European Child & Adolescent Psychiatry},
  year = {2025},
  volume = {34},
  number = {7},
  pages = {2083--2091},
  doi = {10.1007/s00787-024-02623-3}
}
Kostenlos starten →